4.8 Article

Bioactive glass nanoparticles inhibit osteoclast differentiation and osteoporotic bone loss by activating lncRNA NRON expression in the extracellular vesicles derived from bone marrow mesenchymal stem cells

期刊

BIOMATERIALS
卷 283, 期 -, 页码 -

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2022.121438

关键词

Bioactive glass; Extracellular vesicles; lncRNA NRON; Osteoporosis

资金

  1. National Key R&D Program of China [2017YFC1105000, 2018YFC1106300]
  2. National Natural Science Foundation of China [51572087,32000933, 81972080, U1501245, 51672088]
  3. GDST-NWO science industry cooperation programme Chemistry [2018A050501006]
  4. Science and Technology Planning Project of Guangdong Province [2017B030314139]
  5. Science and Technology Planning Project of Guangzhou [202102080527]
  6. Ministry of Education, China-111 Project [B13039]

向作者/读者索取更多资源

This study reveals a new mechanism by which bioactive glass nanoparticles (BGN) regulate bone loss through inducing the secretion of extracellular vesicles (EVs) by bone marrow mesenchymal stem cells (BMSCs). The EVs inhibit osteoclast differentiation by reducing the nuclear translocation of NFATc1. Furthermore, BGN+BMSC-EVs show potential in alleviating bone loss in an osteoporosis mouse model, with no acute systemic toxicity.
Bioactive glass nanoparticles (BGN) have attracted increasing attention for their use in bone tissue repair owing to their special osteogenic activity; however, the underlying molecular mechanism remains unclear. In this study, we report a new mechanism by which BGN regulate bone loss in an osteoporosis mouse model. We found that BGN induced the expression of extracellular vesicles secreted by bone marrow mesenchymal stem cells (BGN + BMSC-EVs), which can inhibit osteoclast differentiation in vitro. Furthermore, our results showed that BGN + BMSC-EVs were rich in the long non-coding RNA NRON, which can inhibit the nuclear translocation of NFATc1 by binding to the nuclear factor of activated T cells transcription factors, thereby inhibiting osteoclast differentiation. We validated the function and biological safety of BGN + BMSC-EVs in an ovariectomized mouse model of osteoporosis. The results of in vivo studies showed that BGN + BMSC-EVs could alleviate bone loss in osteoporotic mice, restore the mechanical properties of mouse femurs, and improve the biochemical indicators in the peripheral blood for bone metabolism in mice, with little to no acute, systemic toxicity. This study may provide a new explanation for the role of BGN in inhibiting osteoclast differentiation and relieving bone loss; additionally, the study findings reveal a promising strategy for the treatment of bone resorption disorders.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据